Press Room

Event

2024 AIChE Annual meeting

Start

Sunday, October 27, 2024 - 08:00

End

Thursday, October 31, 2024 - 18:00

Location: San Diego, United States

Meet Hovione team at the 2024 AIChE Annual Meeting and find their exciting presentations and Hovione’s latest research and innovations. The AIChE Annual Meeting is an educational forum covering a wide range of topics relevant to cutting-edge research, new technologies, and emerging growth areas in chemical engineering. We look forward to meeting academic and industry experts and exchanging knowledge.

Date: October 28, 2024

Oral Presentation

Title: High Pressure Reaction Kinetic Modeling: Leveraging Single Data-Rich Experiment

Presenting Author: Ines Rocha – Scientist, Process Scale-up

9:45 AM - 10:06 AM

Room 29C (Upper Level, SDCC)

Oral Presentation

Title: Integrating Amorphous Solid Dispersions (ASDs) in a PBPK Software

Presenting Author: Pedro Monteiro – Senior Scientist, Formulation Development

10:06 AM - 10:27 AM

Room 29D (Upper Level, SDCC)

Oral Presentation

Title: Comprehensive Powder Flow Characterization with Reduced Testing

Presenting Author: Maria Paisana – Senior Scientist, Lead Analytical Scientists

12:50 PM - 1:10 PM

Sapphire 400B (4, Hilton Bayfront)

Oral Presentation

Title: Bayesian Optimization Applied to Chemical Reaction Optimization: Human-in-Loop and Cdmo Perspective

Presenting Author: Ines Rocha – Scientist, Process Scale-up

12:50 PM - 1:10 PM

Room 29D (Upper Level, SDCC)

Date: October 29, 2024

Oral Presentation

Title: Tswg Development and Scale up from Laboratory Benchtop Experiments

Presenting Author: Ricardo Sousa – Senior Scientist, Formulation Development

8:30 AM - 8:45 AM

Cobalt 520 (5, Hilton Bayfront)

Oral Presentation

Title: Scaling Continuous Powder Blenders: The Length-Scale Problem

Presenting Author: Scientific Fellow, Continuous Tableting

1:06 PM - 1:24 PM

Sapphire Ballroom M (4, Hilton Bayfront)

Date: October 30, 2024

Oral Presentation

Title: Path to Commercial Reality of Continuous Manufacturing - a Cdmo Perspective

Presenting Author: Jose Luis Santos – R&D Director, Technology Intensification

9:45 AM - 10:06 AM

Room 29C (Upper Level, SDCC)

Oral Presentation

Title: Methodology for Rapid Development of a Continuous Loss-in-Weight Feeding Process

Presenting Author: Ana Martins – PhD Student

1:12 PM - 1:33 PM

Room 29C (Upper Level, SDCC)

Poster Presentation

Title: Direct Scale-up of a Dry Granulation Process Using a Material Lean Approach at Lab-Scale

Presenting Author: Ricardo Sousa – Senior Scientist, Formulation Development

10:06 AM - 10:27 AM

Exhibit Hall GH (Ground Level, SDCC)

Date: October 31, 2024

Oral Presentation

Title: Formulating Amorphous Solid Dispersions into Oral Dosage Forms: A Fast to Market Integrated Approach

Presenting Author: Patricia Cruz

12:51 PM - 1:12 PM

Room 29C (Upper Level, SDCC)

Oral Presentation

Title: Leveraging COSMO-RS for Chemical Development and Scale-up in the Pharmaceutical Industry

Presenting Author: Ines Rocha – Scientist, Process Scale-up

3:30 PM - 3:48 PM

Room 30E (Upper Level, SDCC)

Let’s discuss your project together.

Find more about AIChE Annual Meeting

You might be interested in:

Drug Substance at Hovione

Your partner in custom development and manufacturing of APIs.

The Leader in Spray Drying

Know how to overcome your solubility issues with the best scale-up science.

The Future is Continuous

Meet our experts and find out if Continuous Tableting is right for your product.

Industrialization of Innovative Platforms

Learn more about our Large-scale GMP-compliant platforms that support your project from development to commercialization.

Also in the Press Room

See All

The CDMO’s New Jersey manufacturing site expansion will eventually cover more than 200,000 square feet. Portugal-based contract development and manufacturing organisation (CDMO) Hovione has completed an initial $100 million investment round in its East Windsor, New Jersey site. Once completed it will increase the facility’s footprint to more than 200,000 square feet and more than double its capacity for spray drying. Hovione CEO Jean-Luc Herbeaux said: “Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. “This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the US, we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.” Spray drying is an increasingly important particle engineering technology for improving drug bioavailability through the amorphous solid dispersion (ASD) that can address bioavailability or crystallisation challenges. The initial phase of Hovione’s expansion will include a 31,000-square-foot building to house two size-3 spray dryers (PSD-3) designed for ASD production. Construction at the New Jersey site is already underway and the company plans to start GMP operations in the second quarter of 2026. The initiative is part of Hovione’s long-term strategy to grow its US operations and enhance its integrated drug substance, drug product intermediate and drug product capabilities. Herbeaux said: “This investment addresses growing customer demand for US-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.” The company’s New Jersey expansion fits into its wider international growth plan that also includes capacity investments in Ireland and Portugal as it seeks to create a network of autonomous sites spanning the development and commercialisation of APIs, drug product intermediates and drug products. Read the full article at EuropeanPharmaceuticalReview.com

Press Clipping

European Pharmaceutical Review, 4 November 2025

Hovione doubles spray drying capacity with $100m US investment round

Nov 04, 2025

US-base manufacturing and the continued rise of peptides were among the key themes for CDMOs at CPHI Frankfurt 2025. Andrew Warmington reports. Hovione announced during this show that it has completed an initial $100 million investment phase in the expansion of its manufacturing footprint in East Windsor, New Jersey. The company was one of the first European CDMOs to set up in the US back in 2002. CEO Jean-Luc Herbeaux said that when he took over the role four years ago, Hovione's footprint in the US was limited and the site was reaching capacity limitations. (...) Read the full article on SpecChemOnline.com

Article

Speciality Chemicals, Nov./Dec. 2025

Coming to America - Drug Product Focus

Nov 01, 2025

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet. The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026. As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities. Read the full article at DCATvci.org

Press Clipping

DCAT Value Chain Insights, 30 October 2025